Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 18/20 | 0.83 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5469113 | 0.91 | PTGER1 (1.00) | PTGER1MRGPRX4 | |
| SCHEMBL4683848 | 0.89 | PTGER1 (0.66) | PTGER1TBXA2RPTGER4PTGER3 | |
| SCHEMBL4684002 | 0.88 | PTGER1 (0.70) | PTGER1MRGPRX4 | |
| SCHEMBL4686282 | 0.88 | PTGER1 (0.70) | PTGER1 | |
| SCHEMBL4684120 | 0.87 | PTGER1 (0.63) | PTGER1TBXA2RPTGER4PTGER3 | |
| SCHEMBL4684051 | 0.87 | PTGER1 (0.74) | PTGER1TBXA2RPTGER3MRGPRX4 | |
| SCHEMBL4683334 | 0.85 | PTGER1 (0.78) | PTGER1MRGPRX4 | |
| SCHEMBL4680758 | 0.81 | PTGER1 (0.81) | PTGER1 | |
| SCHEMBL34470012 | 0.80 | KLKB1 (0.50) | PTGER1 | |
| SCHEMBL14774654 | 0.79 | PTGER1 (0.53) | PTGER1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675832-B1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | claimed |
| EP-1675832-B1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-20070060596-A1 | Heterocyclyl compounds | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| US-20070060596-A1 | Heterocyclyl compounds | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060596-A1 | Heterocyclyl compounds | F9, F12, CYP2C9 | PTGER1 1257/4885TBXA2R 48/4885PTGER4 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.